Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | NAMPT | P43490 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2793503 | 0.89 | ROCK2 (0.54) | ROCK2ROCK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2790669 | 0.88 | MEN1 (0.61) | ROCK2ROCK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL3501882 | 0.83 | LMNA (0.55) | ROCK2ROCK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2790193 | 0.83 | ROCK2 (0.55) | ROCK2ROCK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2795473 | 0.83 | NT5E (0.66) | ROCK2ROCK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL3501458 | 0.81 | SMN1; SMN2 (0.55) | ROCK2ROCK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2794381 | 0.81 | ROCK2 (0.64) | ROCK2ROCK1SMN1; SMN2ALDH1A1NAMPT | |
| SCHEMBL2796143 | 0.81 | ROCK2 (0.55) | ROCK2ROCK1SMN1; SMN2NAMPTMEN1 | |
| SCHEMBL2793151 | 0.81 | ROCK2 (0.58) | ROCK2ROCK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2790457 | 0.81 | ROCK2 (0.55) | ROCK2ROCK1LMNASMN1; SMN2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | MAP3K1, CDK1, CDK2 | ROCK2 528/4885ROCK1 414/4885LMNA 1207/4885 |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | MAP3K1, CDK1, CDK2 | ROCK2 528/4885ROCK1 414/4885LMNA 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.